- Home
- HTBK vs TBPH Comparison
HTBK vs TBPH Comparison
Compare HTBK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBK
- TBPH
- Stock Information
- Founded
- HTBK 1997
- TBPH 2013
- Country
- HTBK United States
- TBPH United States
- Employees
- HTBK N/A
- TBPH N/A
- Industry
- HTBK Major Banks
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- HTBK Finance
- TBPH Health Care
- Exchange
- HTBK Nasdaq
- TBPH Nasdaq
- Market Cap
- HTBK 586.0M
- TBPH 485.8M
- IPO Year
- HTBK 1998
- TBPH N/A
- Fundamental
- Price
- HTBK $9.59
- TBPH $9.59
- Analyst Decision
- HTBK Buy
- TBPH Buy
- Analyst Count
- HTBK 3
- TBPH 4
- Target Price
- HTBK $11.50
- TBPH $13.75
- AVG Volume (30 Days)
- HTBK 341.1K
- TBPH 217.1K
- Earning Date
- HTBK 01-23-2025
- TBPH 11-12-2024
- Dividend Yield
- HTBK 5.42%
- TBPH N/A
- EPS Growth
- HTBK N/A
- TBPH N/A
- EPS
- HTBK 0.71
- TBPH N/A
- Revenue
- HTBK $169,172,000.00
- TBPH $63,192,000.00
- Revenue This Year
- HTBK N/A
- TBPH $11.41
- Revenue Next Year
- HTBK $5.65
- TBPH $37.36
- P/E Ratio
- HTBK $13.58
- TBPH N/A
- Revenue Growth
- HTBK N/A
- TBPH 15.93
- 52 Week Low
- HTBK $7.66
- TBPH $7.44
- 52 Week High
- HTBK $11.27
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- HTBK 29.47
- TBPH 50.13
- Support Level
- HTBK $10.24
- TBPH $9.62
- Resistance Level
- HTBK $10.50
- TBPH $10.08
- Average True Range (ATR)
- HTBK 0.30
- TBPH 0.31
- MACD
- HTBK -0.13
- TBPH -0.06
- Stochastic Oscillator
- HTBK 8.06
- TBPH 25.00
About HTBK Heritage Commerce Corp
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two segments, namely Banking and Factoring. The bank generates its revenue from the Banking segment.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).